항혈전약 시장 규모, 점유율 및 성장 분석 : 유형별, 약제 클래스별, 적응증별, 투여 경로별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)

Global Antithrombotic Drugs Market size was valued at USD 52.22 Billion in 2024 and is poised to grow from USD 56.35 Billion in 2025 to USD 103.53 Billion by 2033, growing at a CAGR of 7.9% during the forecast period (2026-2033).

The market for antithrombotic drugs is significantly influenced by the increasing prevalence of cardiovascular diseases, a growing geriatric population, and a rising demand for novel oral anticoagulants (NOACs). Cardiovascular conditions, including atrial fibrillation and venous thromboembolism, represent a leading cause of mortality globally, thereby heightening the need for effective antithrombotic therapies. The elderly are particularly susceptible to thrombotic disorders, expanding the patient demographic. The popularity of NOACs, such as dabigatran and rivaroxaban, is surging due to their ease of use, minimal drug interactions, and lower bleeding risks, which is propelling market expansion. However, challenges like heightened bleeding risks, the high expense of NOACs, gastrointestinal complications, stringent regulations, and apprehension about side effects continue to constrain market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Antithrombotic Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Antithrombotic Drugs Market Segments Analysis

Global Antithrombotic Drugs Market is segmented by Type, Drug Class, Indication, Route of Administration, End User, Distribution Channel and region. Based on Type, the market is segmented into Apixaban, Debigatran, Edoxaban, Fondaparinux, Heparin and Rivaroxaban. Based on Drug Class, the market is segmented into Thrombolytic Drugs, Anti-Platelet Drugs, Anticoagulants and Others. Based on Indication, the market is segmented into Atrial Fibrillation, Stroke, Deep vein thrombosis (DVT), Pulmonary Embolism (PE) and Others. Based on Route of Administration, the market is segmented into Oral, Injectable and Others. Based on End User, the market is segmented into Hospitals, Specialty Clinics, Homecare and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Antithrombotic Drugs Market

The increasing incidence of cardiovascular conditions such as atrial fibrillation, deep vein thrombosis, and stroke significantly drives the demand for antithrombotic drugs. Contributing factors include an expanding population, sedentary lifestyles, and the prevalence of metabolic syndrome, which together highlight the critical role of anticoagulants and antiplatelet medications. These therapies are essential not only for the immediate management of acute events but also for the long-term reduction of cardiovascular risks. As awareness of these health issues continues to rise, the market for antithrombotic medications is expected to expand, reflecting the need for effective treatment options.

Restraints in the Global Antithrombotic Drugs Market

The Global Antithrombotic Drugs market faces significant challenges due to the inherent risk of bleeding associated with these medications, particularly for elderly patients or individuals with pre-existing health conditions. This elevated risk complicates clinical decision-making processes, often necessitating continuous monitoring, adjustments in dosage, or even discontinuation of therapy. Such safety concerns can undermine the confidence of healthcare providers and lead to decreased patient adherence to prescribed regimens. Consequently, these factors can severely impact both the overall market penetration of antithrombotic treatments and the effectiveness of long-term maintenance therapies, ultimately affecting patient outcomes.

Market Trends of the Global Antithrombotic Drugs Market

The global antithrombotic drugs market is witnessing a notable trend toward next-generation targeted therapies that promise enhanced specificity in coagulation factor modulation. This innovative approach is focused on developing ultra-targeted treatments with reduced bleeding risks and sustained therapeutic efficacy. By honing in on specific pathological processes, these advanced antithrombotic agents are designed to minimize side effects associated with traditional therapies, paving the way for more personalized treatment strategies. As a result, healthcare providers can better balance the prevention of clotting with the control of bleeding, meeting the evolving needs of patients and driving growth in the antithrombotic market.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Customer Buying Behavior Analysis

Global Antithrombotic Drugs Market Size by Type & CAGR (2026-2033)

• Market Overview
• Apixaban
• Debigatran
• Edoxaban
• Fondaparinux
• Heparin
• Rivaroxaban

Global Antithrombotic Drugs Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Thrombolytic Drugs
• Anti-Platelet Drugs
• Anticoagulants
• Others

Global Antithrombotic Drugs Market Size by Indication & CAGR (2026-2033)

• Market Overview
• Atrial Fibrillation
• Stroke
• Deep vein thrombosis (DVT)
• Pulmonary Embolism (PE)
• Others

Global Antithrombotic Drugs Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Injectable
• Others

Global Antithrombotic Drugs Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialty Clinics
• Homecare
• Others

Global Antithrombotic Drugs Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Global Antithrombotic Drugs Market Size & CAGR (2026-2033)

• North America (Type, Drug Class, Indication, Route of Administration, End User, Distribution Channel)
  • US
  • Canada
• Europe (Type, Drug Class, Indication, Route of Administration, End User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Drug Class, Indication, Route of Administration, End User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Drug Class, Indication, Route of Administration, End User, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Drug Class, Indication, Route of Administration, End User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (U.K.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergan (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (U.K.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Private Limited (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hikma Pharmaceuticals PLC (U.K.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius Kabi AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eisai Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DAIICHI SANKYO COMPANY, LIMITED (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations